01.12.2022 • NewsEuropean Commission (EC)styreneIneos

EU Fines Styrene Buyers for Cartel

The European Commission has fined five companies a total of €157 million for forming a styrene cartel that operated from May 2012 to June 2018. Affected are Sunpor, Synbra, Synthomer, Synthos and Trinseo. As the member that blew the whistle in 2017, Ineos escaped a fine.

© Shutterstock/CX
© Shutterstock/CX

“With our decision today we fine six companies which participated in a purchasing cartel of styrene, a key input for many chemical products,” said the Commission’s executive vice-president Margrethe Vestager, who is also competition commissioner. The companies, she said, “colluded and exchanged information on an industry reference price for styrene. Their plan was to influence the reference price negotiations to their advantage to buy styrene at a lower price.”

Because of the volatility of styrene prices, industry players often use an industry reference price — as published by reporting agency ICIS — as a basis for their supply agreements.

All the players received a 10% reduction in their fines for admitting their involvement. Sunpor, Synthomer, Synthos and Trinseo also received an additional reduction under the Commission’s leniency program for cooperating with the investigation.

Author: Elaine Burridge, Freelance Journalist

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.